Traders sold shares of Bristol-Myers Squibb Co. (NYSE:BMY) on strength during trading on Thursday. $42.86 million flowed into the stock on the tick-up and $63.43 million flowed out of the stock on the tick-down, for a money net flow of $20.57 million out of the stock. Of all stocks tracked, Bristol-Myers Squibb had the 0th highest net out-flow for the day. Bristol-Myers Squibb traded up $0.52 for the day and closed at $75.32

A number of brokerages have issued reports on BMY. Barclays PLC lifted their price objective on Bristol-Myers Squibb from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday, April 29th. Morgan Stanley cut Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating in a report on Friday. Deutsche Bank AG cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Friday. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Friday. Finally, SunTrust Banks Inc. cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating in a report on Friday. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $74.98.

The stock’s 50-day moving average is $73.96 and its 200 day moving average is $68.53. The firm has a market capitalization of $105.73 billion and a price-to-earnings ratio of 37.01.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.66 by $0.03. The firm earned $4.90 billion during the quarter, compared to the consensus estimate of $4.60 billion. Bristol-Myers Squibb’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.53 earnings per share. Equities research analysts anticipate that Bristol-Myers Squibb Co. will post $2.64 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 7th will be given a $0.38 dividend. The ex-dividend date is Wednesday, October 5th. This represents a $1.52 annualized dividend and a yield of 2.40%.

In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 23,200 shares of the stock in a transaction dated Friday, July 8th. The stock was sold at an average price of $74.45, for a total value of $1,727,240.00. Following the completion of the transaction, the director now directly owns 380,099 shares in the company, valued at $28,298,370.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Charles A. Bancroft sold 30,201 shares of the stock in a transaction dated Friday, May 20th. The shares were sold at an average price of $70.79, for a total value of $2,137,928.79. Following the completion of the transaction, the chief financial officer now owns 184,694 shares of the company’s stock, valued at $13,074,488.26. The disclosure for this sale can be found here.

A number of institutional investors have recently bought and sold shares of BMY. Jennison Associates LLC increased its position in Bristol-Myers Squibb by 19.2% in the fourth quarter. Jennison Associates LLC now owns 27,739,860 shares of the biopharmaceutical company’s stock valued at $1,908,225,000 after buying an additional 4,462,075 shares in the last quarter. Westfield Capital Management Co. LP increased its position in Bristol-Myers Squibb by 2,141.4% in the fourth quarter. Westfield Capital Management Co. LP now owns 2,921,174 shares of the biopharmaceutical company’s stock valued at $200,948,000 after buying an additional 2,790,844 shares in the last quarter. Vanguard Group Inc. increased its position in Bristol-Myers Squibb by 2.4% in the fourth quarter. Vanguard Group Inc. now owns 100,977,126 shares of the biopharmaceutical company’s stock valued at $6,946,217,000 after buying an additional 2,396,947 shares in the last quarter. Marshall Wace LLP increased its position in Bristol-Myers Squibb by 173.6% in the fourth quarter. Marshall Wace LLP now owns 2,833,753 shares of the biopharmaceutical company’s stock valued at $194,933,000 after buying an additional 1,798,080 shares in the last quarter. Finally, Brown Advisory Inc. increased its position in Bristol-Myers Squibb by 5.4% in the fourth quarter. Brown Advisory Inc. now owns 8,541,624 shares of the biopharmaceutical company’s stock valued at $587,578,000 after buying an additional 433,894 shares in the last quarter.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in BioPharmaceuticals segment. Its pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.